Press Release: Aqualung Therapeutics : Aqualung Therapeutics, an Immunotherapeutics Biotech Company, Receives ...

(PR-inside.com) -Aqualung will present at the annual Biotech Showcase conference in San Francisco on January 10, 2023. -JSR Lifesciences invested $1.5M toward the preferred series A capital raise, October 2022. -The dosing of the P1A Healthy Human Volunteer Study with ALT-100 mAb is nearing completion, with no reported SAEs to date. Study to conclude by Q2 2023. TUCSON, AZ / ACCESSWIRE / December 5, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics company with an anti-inflammatory and anti-fibrotic therapeutic platform for life-threatening unchecked inflammation/fibrosis, will be presenting at the annual Biotech Showcase in San Francisco in conjunction with the JP Morgan ..